NEWS. RESOURCES. DADVICE. THE HOME OF MEN-TERTAINMENT

Here are the 3 most heavily traded ASX 200 shares on Monday

SHARE

The S&P/ASX 200 Index (ASX: XJO) is off to a cracking start to the trading week so far this Monday. At the time of writing, the ASX 200 has galloped ahead, rising by 1.92% to just over 6,700 points.

But let’s delve a little deeper into these ASX gains and have a look at the ASX 200 shares that are currently at the peak of the share market’s volume charts right now, according to investing.com.

Lake Resources N.L. (ASX: LKE)

First up today, we have an ASX 200 resources share in Lake Resources. So far this Monday, a whopping 36.77 million Lake Resources shares have been bought and sold.

In some good news, this volume seems to be a byproduct of the huge rally we are seeing in lithium stocks over today’s session. Like many of its peers today, Lake Resources shares are on fire. In this case, the company has put on a pleasing 6.52% at the time of writing, trading at 85.75 cents a share.

Evolution Mining Ltd (ASX: EVN)

Our next ASX 200 share to check out today is the gold miner Evolution Mining. So far today, a sizeable 36.98 million Evolution shares have been shared around the ASX. Unfortunately for investors, it’s been some terrible news that has elicited this high volume.

As we covered this morning, the miner updated its FY2022 guidance. It reported that it expects its full-year production to fall 6% year-on-year, while costs are set to rise. This has led to a brutal share price reaction, with Evolution shares falling by almost 22% today. No wonder so many shares have been traded.

Imugene Limited (ASX: IMU)

Finally, we have ASX 200 healthcare share Imugene. A massive 85.59 million Imugene shares have changed hands so far today. In another bit of good news for investors, we seem to have another huge share price spike to thank here.

Imugene shares are presently up a jaw-dropping 46.67% at 24.2 cents each. This comes after the company reported some pleasing results this morning on its gastric cancer drug candidate HER-Vaxx. With a rise of that scale, it’s no wonder we are seeing such impressive volumes today.

Source: Read More

We’ve Already Come Too Far To End This Now.

Subscribe To Our Weekly Newsletter

Get notified about new articles